A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane.

Trial Profile

A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2012

At a glance

  • Drugs Apricoxib; Capecitabine; Lapatinib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms APRiCOT-B
  • Sponsors Tragara Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2012 Planned End Date changed from 1 Jun 2010 to 1 Sep 2009 as reported by ClinicalTrials.gov.
    • 30 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Planned end date changed from 1 Jun 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top